| Autor: |
Kourtis K; Department of Cardiology, Konstantopouleio General Hospital, 14233 Athens, Greece., Bourazana A; Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece., Xanthopoulos A; Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece., Skoularigkis S; Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece., Papadakis E; Department of Cardiology, Konstantopouleio General Hospital, 14233 Athens, Greece., Patsilinakos S; Department of Cardiology, Konstantopouleio General Hospital, 14233 Athens, Greece., Skoularigis J; Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece. |
| Jazyk: |
angličtina |
| Zdroj: |
Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2024 Jan 16; Vol. 60 (1). Date of Electronic Publication: 2024 Jan 16. |
| DOI: |
10.3390/medicina60010166 |
| Abstrakt: |
Background and Objectives : Remote ischemic preconditioning (RIPC) has demonstrated efficacy in protecting against myocardial ischemia-reperfusion injury when applied before percutaneous coronary revascularization. Ranolazine, an anti-ischemic drug, has been utilized to minimize ischemic events in chronic angina patients. However, there is a lack of trials exploring the combined effects of ranolazine pretreatment and RIPC in patients undergoing percutaneous coronary interventions (PCIs). Materials and Methods: The present study is a prospective study which enrolled 150 patients scheduled for nonemergent percutaneous coronary revascularization. Three groups were formed: a control group undergoing only PCIs, an RIPC group with RIPC applied to either upper limb before the PCI (preconditioning group), and a group with RIPC before the PCI along with prior ranolazine treatment for stable angina (ranolazine group). Statistical analyses, including ANOVAs and Kruskal-Wallis tests, were conducted, with the Bonferroni correction for type I errors. A repeated-measures ANOVA assessed the changes in serum enzyme levels (SGOT, LDH, CRP, CPK, CK-MB, troponin I) over the follow-up. Statistical significance was set at p < 0.05. Results : The ranolazine group showed (A) significantly lower troponin I level increases compared to the control group for up to 24 h, (B) significantly lower CPK levels after 4, 10, and 24 h compared to the preconditioning group ( p = 0.020, p = 0.020, and p = 0.019, respectively) and significantly lower CPK levels compared to the control group after 10 h ( p = 0.050), and (C) significantly lower CK-MB levels after 10 h compared to the control group ( p = 0.050). Conclusions : This study suggests that combining RIPC before scheduled coronary procedures with ranolazine pretreatment may be linked to reduced ischemia induction, as evidenced by lower myocardial enzyme levels. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
